YD Bio Limited (NASDAQ:YDES) Sees Large Increase in Short Interest

Posted by Doug Wharley on Oct 11th, 2026

YD Bio Limited (NASDAQ:YDES – Get Free Report) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 177,332 shares, a growth of 312.8% from the September 15th total of 42,960 shares. Based on an average daily volume of 728,505 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.3% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of YD Bio to a “hold” rating in a report on Saturday, September 26th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, YD Bio has an average rating of “Sell”.

Read Our Latest Report on YD Bio

Institutional Investors Weigh In On YD Bio

A hedge fund recently raised its position in YD Bio stock. Cypress Capital Management LLC WY raised its holdings in shares of YD Bio Limited (NASDAQ:YDES – Free Report) by 9.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,690 shares of the biotechnology company’s stock after purchasing an additional 3,000 shares during the quarter. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 as of its most recent filing with the Securities & Exchange Commission.

YD Bio Stock Performance

NASDAQ YDES traded up $0.94 on Friday, reaching $6.73. The company had a trading volume of 207,612 shares, compared to its average volume of 595,492. YD Bio has a 12 month low of $1.70 and a 12 month high of $22.00. The firm’s 50 day moving average price is $4.27 and its 200 day moving average price is $4.19.

YD Bio (NASDAQ:YDES – Get Free Report) last issued its earnings results on Tuesday, September 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $0.42 million during the quarter.